NICE Issues Final Draft OK For Brilique

The UK National Institute for Health and Clinical Excellence (NICE) has issued a final draft guidance recommending the use of AstraZeneca’s antiplatelet drug Brilique (ticagrelor) in the treatment of acute coronary syndromes (ACS). Every year, around 200,000 people in England are diagnosed with acute coronary syndromes, which cover a range of conditions from unstable angina

Continue Reading

NICE Rejects BMS’ Orencia For RA

NICE (the National Institute for Health and Clinical Excellence) has issued final guidance rejecting the use of Bristol-Myers Squibb’s Orencia (abatacept) as a second-line treatment for rheumatoid arthritis (RA). The guidance says that the use of Orencia is not recommended in combination with methotrexate for treating RA in adults whose disease has responded inadequately to

Continue Reading

Novartis MS pill rejected by NICE

The decision by the UK’s cost watchdog to reject Novartis’ Gilenya, the first pill to treat multiple sclerosis, has been greeted with dismay by the company and patient groups. In provisional draft guidance published this morning, the National Institute for Health and Clinical Excellence has decided against recommending payment by the National Health Service for

Continue Reading